<SEC-DOCUMENT>0001571049-17-006280.txt : 20170627
<SEC-HEADER>0001571049-17-006280.hdr.sgml : 20170627
<ACCEPTANCE-DATETIME>20170627105311
ACCESSION NUMBER:		0001571049-17-006280
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170623
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170627
DATE AS OF CHANGE:		20170627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		17931454

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1700405_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
June 23, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Sciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification No.)</P></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744;</P>


<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01&nbsp;&nbsp;Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 23, 2017, Applied DNA Sciences, Inc. (&ldquo;Applied
DNA Sciences&rdquo; or the &ldquo;Company&rdquo;) entered into a new licensing agreement (the &ldquo;Agreement&rdquo;) with Himatsingka
<FONT STYLE="color: windowtext">America, Inc.(&ldquo;HAI&rdquo;). The Agreement terminates an earlier licensing agreement dated
March 25, 2015 between Divatex Home Fashion, Inc. (a predecessor to HAI) and the Company. Under the terms of the Agreement, HAI
will be solely responsible for promoting, marketing and selling on a worldwide basis the Company&rsquo;s technology with respect
to finished and unfinished cotton products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Agreement grants HAI an exclusive license to use the Company&rsquo;s
technology in respect of cotton, subject to certain carve-outs including governmental users, non-commercial trade associations
and others. The Agreement has a term that continues until June 23, 2042, except in the case of patents, in which case the term
continues with respect to a patent until such patent is no longer in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Agreement provides that HAI will make payments for the
use of the Company&rsquo;s taggant technology on a net 60 days basis. In addition, HAI will make royalty payments on a quarterly
basis in arrears in the event the Company&rsquo;s technology is used on non-home products. HAI is responsible for the inspection
and compliance within the supply chain.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HAI is generally required to use the Company&rsquo;s technology
during the term of the Agreement, subject, among other things, to their customers&rsquo; requirements. The Company will be required
by the licensing agreement to establish an independent testing laboratory in Ahmedabad, India. The Agreement includes customary
mutual indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 27, 2017, Applied DNA Sciences, Inc. (&ldquo;Applied
DNA Sciences&rdquo; or the &ldquo;Company&rdquo;) issued a press release announcing that it entered into the Agreement. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information related to the press release furnished pursuant
to this Item 1.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities under that Section and
shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press Release of Applied DNA Sciences, Inc. dated June
27, 2017 regarding entering into a new licensing agreement with Himatsingka America, Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27 2017</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated June 27, 2017 regarding entering into a new licensing agreement with Himatsingka America, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1700405_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="t1700405_logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -9pt">Applied DNA Sciences Signs
New Licensing Agreement with Himatsingka America.</P>

<P STYLE="color: #00B0F0; font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 4pt; text-align: center"><FONT STYLE="font-weight: normal; color: Black">New
Agreement to Empower Large Scale Supply Chain Security within the Cotton Industry</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">STONY BROOK, N.Y.
June 27th, 2017: Applied DNA Sciences, Inc. (&ldquo;Applied DNA,&rdquo; &ldquo;the Company,&rdquo; NASDAQ: APDN), is pleased to
announce the signing of a new licensing agreement with Himatsingka America, Inc. (&ldquo;Himatsingka&rdquo;, &ldquo;HAI&rdquo;),
which is a part of the Himatsingka Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&ldquo;This new
agreement represents a strengthened partnership between Applied DNA and Himatsingka, as both companies are committed to meeting
the need for supply chain traceability, transparency and trust within the cotton industry. Applied DNA is looking forward to continuing
to work with the Himatsingka Group, and we are excited at the opportunity to expand market awareness and implement the technology
into additional cotton supply chains.&rdquo; stated Dr. James A. Hayward, President and CEO of Applied DNA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Commenting on the
development, Shrikant Himatsingka, the Managing Director &amp; CEO - Himatsingka Group, said: &ldquo;We look forward to taking
the Applied DNA technology platform global and continuing to bring cutting edge track and trace capabilities to benefit stakeholders
across the cotton value chain. The Himatsingka Group will leverage its world-class manufacturing and distribution capabilities
to ensure that these innovations by Applied DNA find their place across global shelves and penetrate new categories of products.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>About Himatsingka
America</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Himatsingka America
is a part of The Himatsingka Group. The Himatsingka Group is a vertically integrated home textile major with a global footprint.
On the manufacturing front, the group operates one of the largest capacities in the world for producing bed linen, ultrafine count
cotton yarn, drapery and upholstery products. Spread across Asia, Europe and North America, its retail and wholesale distribution
divisions carry some of the most prestigious brands in the home textile space and caters to private label programs of major retailers
across these geographies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>About Applied
DNA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Applied DNA is a provider of molecular
technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass
production for diagnostics and therapeutics.<BR>
<BR>
We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products,
brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud
and diversion. The proprietary DNA-based &ldquo;CertainT&trade;&rdquo; platform can be used to identify, tag, test, and track
products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature<SUP>&reg;</SUP>
DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions
such as SigNature<SUP>&reg;</SUP> T and fiberTyping<SUP>&reg;</SUP>, targeted toward textiles and apparel, BackTrac&trade; and
DNAnet<SUP>&reg;</SUP>, for anti-theft and loss prevention, and digitalDNA<SUP>&reg;</SUP>, providing powerful track-and-trace.
All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the
large-scale production of specific DNA sequences using the polymerase chain reaction.</FONT></P>



<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Visit <U>adnas.com
</U>for more information. Follow us on <U>Twitter</U> and <U>LinkedIn</U>. Join our <U>mailing list</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Common stock listed
on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">The statements
made by APDN in this press release may be &ldquo;forward-looking&rdquo; in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe APDN&rsquo;s future plans, projections, strategies and expectations,
and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual
results could differ materially from those projected due to our short operating history, limited financial resources, limited
market acceptance, market competition and various other factors detailed from time to time in APDN&rsquo;s SEC reports and filings,
including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on
February 9, 2017, and May 11, 2017 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated
events, unless otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>Investor contact:
</B><U>Sanjay Hurry</U><B>,</B> LHAI<B>, &nbsp;</B>212-838-3777</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>media contact</B>:
<U>Angie Mathews</U>, CGPR, 714-768-1140</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>program contact:
</B><U>MeiLin Wan</U>, 631-240-8849&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>web:&nbsp;</B><U>www.adnas.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>twitter: </B>@APDN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Gainsboro 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>t1700405_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1700405_logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ + $9 P$1  (1 0,1 ?_$ +4   $"!P$
M       ("0$" P0%!PH& 0$  04! 0               P$"!08'! @0   %
M! $# P("!@@#"0$   $" P0%$08'"  A$@DQ01,B%%$588$R(Q87<:%2,R0E
M& J1T9+PL<%"LM)3594:$0 ! P,# 04$!P8$!P     !  (#$00%(1(&,4%1
M(A,'87&1%(&AP=$R4B/PL4(S4Q9#<R058K+28Y,T5/_:  P# 0 "$0,1 #\
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#B__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
